Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

1 of 14 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

6(40.0%)

Phase 1

4(26.7%)

Phase 3

3(20.0%)

Phase 4

2(13.3%)

15Total

Phase 2(6)

Phase 1(4)

Phase 3(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT06920771Phase 3Active Not Recruiting

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

Role: lead

NCT02991885Phase 1Completed

HAL-MPE1 Safety and Tolerability Study

Role: lead

NCT02556801Phase 2Completed

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Role: lead

NCT03758456Phase 1Completed

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Role: lead

NCT02231307Phase 3Completed

SUBLIVAC FIX Birch Phase III Short-term Efficacy